Objective: Continuous temperature monitoring in high-risk patients can enable healthcare providers to remotely track patients' temperatures, promptly detect fevers and timely intervene to improve clinical outcomes. We evaluated if a novel wearable, continuous temperature monitor (Verily Patch) can reliably estimate body temperature and early detect fevers in an outpatient setting in patients at a high risk of febrile neutropenia (FN) who recently underwent chemotherapy and autologous stem cell transplantation (ASCT). Methods: 86 patients at a high risk for FN were prospectively enrolled at Mayo Clinic, MN. Patients wore the device in their axilla region for 7 days post ASCT and recorded self-measured oral temperatures every 3 hours. Patients were also followed using clinical standard-of-care procedures with daily oral temperature assessment. The clinic- and patient-assessed oral temperatures were used to develop and evaluate Verily Patch's body temperature and early fever detection algorithms using a K-fold cross-validation approach. Results: The Verily Patch reliably measured body temperatures with an error of 0.35 ± 0.88°F in comparison to clinic- and patient-assessed oral temperatures. The sensitivity and specificity of the patch in detecting clinic-assessed fever episodes was 90.2% and 87.8%. The patch detected 14.3 times the number of clinic-assessed fever episodes with a median lead time of 4.3 hours. Conclusion: Patient self-monitoring of temperature and fever incidents suffers from low accuracy and is impractical for extended periods of time. Continuous temperature monitoring by a wearable device (such as Verily Patch) has the potential to overcome these challenges resulting in better patient clinical outcomes and more cost-effective care.
Objective: Continuous temperature monitoring in high-risk patients can enable healthcare providers to remotely track patients' temperatures, promptly detect fevers and timely intervene to improve clinical outcomes. We evaluated if a novel wearable, continuous temperature monitor (Verily Patch) can reliably estimate body temperature and early detect fevers in an outpatient setting in patients at a high risk of febrile neutropenia (FN) who recently underwent chemotherapy and autologous stem cell transplantation (ASCT). Methods: 86 patients at a high risk for FN were prospectively enrolled at Mayo Clinic, MN. Patients wore the device in their axilla region for 7 days post ASCT and recorded self-measured oral temperatures every 3 hours. Patients were also followed using clinical standard-of-care procedures with daily oral temperature assessment. The clinic- and patient-assessed oral temperatures were used to develop and evaluate Verily Patch's body temperature and early fever detection algorithms using a K-fold cross-validation approach. Results: The Verily Patch reliably measured body temperatures with an error of 0.35 ± 0.88°F in comparison to clinic- and patient-assessed oral temperatures. The sensitivity and specificity of the patch in detecting clinic-assessed fever episodes was 90.2% and 87.8%. The patch detected 14.3 times the number of clinic-assessed fever episodes with a median lead time of 4.3 hours. Conclusion: Patient self-monitoring of temperature and fever incidents suffers from low accuracy and is impractical for extended periods of time. Continuous temperature monitoring by a wearable device (such as Verily Patch) has the potential to overcome these challenges resulting in better patient clinical outcomes and more cost-effective care.
Entities:
Keywords:
Continuous temperature monitoring; early fever detection; febrile neutropenia; machine learning; wearable devices
Authors: Kay Wang; Peter Gill; Jane Wolstenholme; Christopher P Price; Carl Heneghan; Matthew Thompson; Annette Plüddemann Journal: Br J Gen Pract Date: 2014-10 Impact factor: 5.386
Authors: Ana Carolina Oliver; Eloisa Riva; Ricardo Mosquera; Sebastian Galeano; Silvia Pierri; Laura Bello; Ada Caneiro; Regis Gai; Andrew Miller; Pablo Muxi Journal: Ann Hematol Date: 2020-02-15 Impact factor: 3.673
Authors: Lindsey Robert Baden; William Bensinger; Michael Angarone; Corey Casper; Erik R Dubberke; Alison G Freifeld; Ramiro Garzon; John N Greene; John P Greer; James I Ito; Judith E Karp; Daniel R Kaul; Earl King; Emily Mackler; Kieren A Marr; Jose G Montoya; Ashley Morris-Engemann; Peter G Pappas; Ken Rolston; Brahm Segal; Susan K Seo; Sankar Swaminathan; Maoko Naganuma; Dorothy A Shead Journal: J Natl Compr Canc Netw Date: 2012-11-01 Impact factor: 11.908